- Home
- RFI vs RENB Comparison
RFI vs RENB Comparison
Compare RFI & RENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RFI
- RENB
- Stock Information
- Founded
- RFI 1992
- RENB 2011
- Country
- RFI United States
- RENB United States
- Employees
- RFI N/A
- RENB N/A
- Industry
- RFI Investment Managers
- RENB Biotechnology: Pharmaceutical Preparations
- Sector
- RFI Finance
- RENB Health Care
- Exchange
- RFI Nasdaq
- RENB Nasdaq
- Market Cap
- RFI 325.8M
- RENB 279.3M
- IPO Year
- RFI N/A
- RENB N/A
- Fundamental
- Price
- RFI $11.69
- RENB $1.67
- Analyst Decision
- RFI
- RENB
- Analyst Count
- RFI 0
- RENB 0
- Target Price
- RFI N/A
- RENB N/A
- AVG Volume (30 Days)
- RFI 69.8K
- RENB 1.5M
- Earning Date
- RFI 01-01-0001
- RENB 02-12-2025
- Dividend Yield
- RFI 8.25%
- RENB N/A
- EPS Growth
- RFI N/A
- RENB N/A
- EPS
- RFI N/A
- RENB N/A
- Revenue
- RFI N/A
- RENB N/A
- Revenue This Year
- RFI N/A
- RENB N/A
- Revenue Next Year
- RFI N/A
- RENB N/A
- P/E Ratio
- RFI N/A
- RENB N/A
- Revenue Growth
- RFI N/A
- RENB N/A
- 52 Week Low
- RFI $9.62
- RENB $0.40
- 52 Week High
- RFI $12.52
- RENB $5.25
- Technical
- Relative Strength Index (RSI)
- RFI 27.95
- RENB 64.47
- Support Level
- RFI $11.52
- RENB $1.50
- Resistance Level
- RFI $12.30
- RENB $2.04
- Average True Range (ATR)
- RFI 0.24
- RENB 0.34
- MACD
- RFI -0.11
- RENB 0.00
- Stochastic Oscillator
- RFI 10.69
- RENB 68.38
About RFI Cohen & Steers Total Return Realty Fund Inc.
Cohen & Steers Total Return Realty Fund Inc is a diversified, closed-end management investment company. Its investment objective is to achieve a high total return through investment in real estate securities. The Fund invests majority of its total assets in the equity securities of real estate companies under normal circumstances, which includes common shares, REITs, rights or warrants, convertible securities, and preferred shares.
About RENB Renovaro Biosciences Inc.
Renovaro Inc is a biopharmaceutical company. It is engaged in developing new immunotherapies to combat cancer and developing a predicative artificial intelligence-based diagnostic methodology for the use of earlier cancer detection.